StreetInsider.com News Articles

Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine

Tue, 13 Oct 2026 09:00:00 -0400

ORLANDO, FL / ACCESS Newswire / October 13, 2026 / RedChip Companies will host an investor webinar on Tuesday, October 20, 2026, at 4:15 p.m. ET with Anixa Biosciences, Inc. (Nasdaq:ANIX), a clinical-stage biotechnology company developing first-in-class therapies to treat and potentially prevent cancer.

The exclusive event will feature Dr. Amit Kumar, Chairman and CEO, who will discuss Anixa's two clinical-stage oncology programs: lira-cel, a novel CAR-T therapy for recurrent, treatment-resistant ovarian cancer, and a breast cancer vaccine with therapeutic and preventive potential. Both programs are being advanced through collaborations with leading research

Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine

Tue, 13 Oct 2026 09:00:00 -0400

Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

Tue, 13 Oct 2026 08:40:00 -0400

Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference

SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for

Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

Tue, 13 Oct 2026 08:40:00 -0400

Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference

H.C. Wainwright Reiterates Buy Rating on Anixa Biosciences (ANIX)

Tue, 06 Oct 2026 07:06:09 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $6.00 price target on Anixa Biosciences (NASDAQ: ANIX).

The analyst commented: "Yesterday, Anixa Biosciences announced that a patient in the ongoing Phase 1 dose-escalating trial of its FSHR-targeted CAR-T therapy (lira-cel) in recurrent ovarian cancer exhibited stable disease 90 days after treatment. This represents the first such response in the company’s CAR-T cell therapy trial. Specifically, the patient was treated in the fifth dose cohort and received a dose of 1x107 CAR-positive cells per kilogram of body weight following lymphodepletion. This is the highest dose level evaluated to date, and no

Anixa reports stable disease result in ovarian cancer CAR-T trial

Mon, 05 Oct 2026 08:20:14 -0400

Anixa Biosciences (NASDAQ: ANIX) announced that a patient in its ongoing Phase 1 clinical trial evaluating its CAR-T therapy for recurrent ovarian cancer showed no cancer progression 90 days after treatment, marking the first stable disease result observed in the trial.

The patient was enrolled in the fifth dose cohort and received a dose of 1×10⁷ CAR-positive cells per kilogram of body weight following lymphodepletion, the highest dose level administered in the study to date. No dose-limiting toxicities have been observed across any patients in the trial.

The study is evaluating liraltagene autoleucel, or lira-cel, a CAR-T therapy targeting the follicle stimulating

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

Mon, 05 Oct 2026 08:15:00 -0400

First patient in current dose cohort exhibited no progression of her cancer three months after
treatment

Multiple patients have survived more than one year, including one beyond two years

No dose-limiting toxicities observed to date

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

Mon, 05 Oct 2026 08:15:00 -0400

First patient in current dose cohort exhibited no progression of her cancer three months after
treatment

Multiple patients have survived more than one year, including one beyond two years

No dose-limiting toxicities observed to date

Anixa treats second patient in ovarian cancer CAR-T trial cohort 5

Thu, 01 Oct 2026 08:35:17 -0400

Anixa Biosciences (NASDAQ: ANIX) announced that a second patient has been treated in the fifth cohort of its ongoing Phase 1 clinical trial evaluating a CAR-T therapy for recurrent ovarian cancer, conducted at Moffitt Cancer Center.

Patients in the fifth cohort receive a dose of 1×10⁷ CAR-positive cells per kilogram of body weight following lymphodepletion, the highest dose level evaluated to date in the study. No dose-limiting toxicities have been observed across any cohort through the first patient treated in the fifth cohort.

The trial targets follicle stimulating hormone receptor (FSHR), which is expressed on ovarian cancer cells with limited expression in

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Thu, 01 Oct 2026 08:35:00 -0400

Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date

Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion

SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Thu, 01 Oct 2026 08:35:00 -0400

Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date

Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion

SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa

Form 4 Anixa Biosciences Inc For: Sep 30 Filed by: Catelani Michael

Wed, 30 Sep 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260930/27126909.html

Form 4 Anixa Biosciences Inc For: Sep 24 Filed by: KUMAR AMIT

Mon, 28 Sep 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260928/27110712.html

Form 4 Anixa Biosciences Inc For: Sep 24 Filed by: Baskies Arnold M

Mon, 28 Sep 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260928/27110614.html

Form 4 Anixa Biosciences Inc For: Sep 23 Filed by: Titterton Lewis H jr

Fri, 25 Sep 2026 08:40:00 -0400

si-local-file:///var/storage/secattach/20260925/27104465.html

Anixa Biosciences (ANIX) PT Lowered to $6 at H.C. Wainwright

Wed, 23 Sep 2026 06:58:27 -0400

(Updated - September 23, 2026 6:58 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on Anixa Biosciences (NASDAQ: ANIX) to $6.00 (from $7.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Anixa Biosciences announced that IP Australia had issued Patent Number 2020221280 related to Anixa's breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. This composition-of-matter patent protects the novel approach to breast cancer prevention and treatment in Australia through 2040. Of note, the Australian patent complements Anixa's existing patent portfolio in the U.S. and other key international markets, including Europe, China, Japan, and South Korea. As a

Anixa Biosciences (ANIX) PT Lowered to $6 at H.C. Wainwright

Wed, 23 Sep 2026 06:58:27 -0400

(Updated - September 23, 2026 6:58 AM EDT)

H.C. Wainwright analyst Yi Chen lowered the price target on Anixa Biosciences (NASDAQ: ANIX) to $6.00 (from $7.00) while maintaining a Buy rating.

Anixa Biosciences receives Australian patent for breast cancer vaccine

Mon, 21 Sep 2026 08:53:55 -0400

Anixa Biosciences, Inc. (NASDAQ: ANIX) has been granted a patent in Australia for its breast cancer vaccine technology, extending intellectual property protection in that market through 2040, according to a company press release.

IP Australia issued Patent Number 2020221280, titled "Vaccine Adjuvants and Formulations," covering a composition-of-matter claim for the vaccine technology exclusively licensed from Cleveland Clinic. The co-inventors are Dr. Justin Johnson and the late Dr. Vincent Tuohy, both of Cleveland Clinic.

The Australian patent adds to Anixa's existing portfolio in the United States, Europe, China, and Japan. The vaccine targets human α-lactalbumin, a protein associated with lactation that the company

Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

Mon, 21 Sep 2026 08:45:00 -0400

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estate

Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates

SAN JOSE, Calif., Sept. 21,

Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

Mon, 21 Sep 2026 08:45:00 -0400

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estate

Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates

SAN JOSE, Calif., Sept. 21,

Anixa Biosciences adds UPenn cancer researcher to advisory board

Wed, 16 Sep 2026 09:15:18 -0400

Anixa Biosciences, Inc. (NASDAQ: ANIX) has appointed Carmen Guerra, M.D., to its Cancer Business Advisory Board, according to a company press release.

Dr. Guerra is a professor of medicine and biostatistics and epidemiology at the Perelman School of Medicine at the University of Pennsylvania. She also serves as Associate Director of Community Outreach and Engagement for the Abramson Cancer Center.

Her research focuses on increasing participation of underserved populations in cancer screening and clinical trials. She oversees the Penn Medicine Colorectal Cancer Screening Navigation Program and the Breast and Cervical Cancer Early Detection Program. She is also the site Principal Investigator of

Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board

Wed, 16 Sep 2026 09:15:00 -0400

SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board.

Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board

Wed, 16 Sep 2026 09:15:00 -0400

Form 4 Anixa Biosciences Inc For: Sep 10 Filed by: KUMAR AMIT

Mon, 14 Sep 2026 09:45:00 -0400

si-local-file:///var/storage/secattach/20260914/27056579.html

Form 4 Anixa Biosciences Inc For: Sep 10 Filed by: Titterton Lewis H jr

Mon, 14 Sep 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260914/27056414.html